Mechanism of thrombin binding to endothelial cells.
The interaction of human alpha-thrombin with mini-pig aortic endothelial cells was studied using 125I-labeled enzyme. Equilibrium between bound and free thrombin was attained within 1 min, and the Klotz-Hunston equations indicated two populations of binding sites. Approximately 30,000 sites/cell belonged to the high-affinity class with a Kd of about 3 x 10(-8) M. Modification of two lysine residues of thrombin with pyridoxal 5'-phosphate (PLP2-thrombin) destroyed the high-affinity binding and about three-fourths of the low-affinity bindings. When the lysine residue of thrombin involved in heparin binding was protected with heparin against chemical modification (PLP-thrombin), the modified enzyme remained similar to the native one with respect to cellular binding, with some loss of low-affinity binding only. Heparin, in a tenfold molar excess to enzyme, inhibited the binding of the native as well as the PLP-thrombin, whereas it did not influence the interaction between PLP2-thrombin and the cell. Since heparin might interfere with both the enzyme and the cell, the binding of heparin to endothelial cells was also examined. The results revealed that 3H-heparin also bound to cells. This binding was characterized by a Kd of 3 x 10(-7) M, approximately 10(6) sites/cell. Furthermore, thrombin bound to endothelial cells was released by antithrombin III. On the basis of these and other data in the literature, a model is proposed for the mechanism of the binding of thrombin to endothelial cells.
D000990:Antithrombin III / Q000494:pharmacology; D001665:Binding Sites; D004727:Endothelium / Q000166:cytology / Q000378:metabolism*; D006493:Heparin / Q000494:pharmacology; D006801:Humans; D008239:Lysine / Q000494:pharmacology; D011732:Pyridoxal Phosphate / Q000494:pharmacology; D013917:Thrombin / Q000378:metabolism*
D011732:Pyridoxal Phosphate; D000990:Antithrombin III; D006493:Heparin; D013917:Thrombin; D008239:Lysine